Allogene Therapeutics, Inc. (ALLO)
USD 1.91
(-7.97%)
USD 1.91
(-7.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 95 Thousand | 243 Thousand | 38.48 Million | - | - | - |
| Cost of Revenue | 242.91 Million | 16.72 Million | 13.06 Million | 11.54 Million | 5.02 Million | 1.5 Million |
| Gross Profit | -242.81 Million | -16.48 Million | 25.42 Million | -11.54 Million | -5.02 Million | -1.5 Million |
| Operating Expenses | 84.91 Million | 335.69 Million | 294.28 Million | 258.24 Million | 202 Million | 192.84 Million |
| Selling, General and Administrative Expenses | 71.67 Million | 79.3 Million | 74.1 Million | 65.25 Million | 57.47 Million | 40.98 Million |
| Research and Development Expenses | 242.91 Million | 256.38 Million | 220.17 Million | 192.98 Million | 144.53 Million | 151.86 Million |
| Other Expenses | -229.66 Million | -1.74 Million | -2.92 Million | -1.14 Million | -268 Thousand | -21.21 Million |
| Cost and Expenses | 327.83 Million | 335.69 Million | 294.28 Million | 258.24 Million | 202 Million | 192.84 Million |
| Operating Income | -327.73 Million | -335.44 Million | -255.79 Million | -258.24 Million | -202 Million | -192.84 Million |
| Interest Expense | - | - | - | - | - | 3.35 Million |
| Income Tax Expense | - | -2.81 Million | -12.16 Million | -16.75 Million | -331 Thousand | -117 Thousand |
| Earnings before Tax | -327.26 Million | -332.63 Million | -257 Million | -250.22 Million | -184.92 Million | -211.62 Million |
| Net Income | -327.26 Million | -329.81 Million | -244.83 Million | -233.47 Million | -184.59 Million | -211.5 Million |
| Earnings Per Share Basic | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 |
| Earnings Per Share Diluted | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 |
| Weighted Average Shares Outstanding | 156.93 Million | 143.14 Million | 135.82 Million | 120.37 Million | 101.06 Million | 28.94 Million |
| Weighted Average Shares Outstanding (Diluted) | 156.93 Million | 143.14 Million | 135.82 Million | 120.37 Million | 101.06 Million | 28.94 Million |
| Gross Margin | -2555.99 | -67.84 | 0.66 | - | - | - |
| EBIT Margin | -3160.98 | -1380.45 | -6.65 | - | - | - |
| Profit Margin | -3444.89 | -1357.26 | -6.36 | - | - | - |
| EBITDA | -300.29 Million | -321.24 Million | -169.73 Million | -250.8 Million | -179.89 Million | -206.76 Million |
| Earnings Before Tax Margin | -3449.86 | -1380.45 | -6.65 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | 22 Thousand | 21 Thousand | 95 Thousand | 43 Thousand | 44 Thousand |
| Cost of Revenue | 3.64 Million | 3.55 Million | 54.66 Million | 242.91 Million | 3.57 Million | 3.79 Million |
| Gross Profit | -3.64 Million | -3.53 Million | -54.64 Million | -242.81 Million | -3.52 Million | -3.74 Million |
| Operating Expenses | 62.79 Million | 65.97 Million | 71.88 Million | 314.58 Million | 63.01 Million | 80.56 Million |
| Selling, General and Administrative Expenses | 16.08 Million | 17.26 Million | 17.22 Million | - | 17.04 Million | 18.52 Million |
| Research and Development Expenses | 46.71 Million | 48.7 Million | 54.66 Million | - | 45.97 Million | 62.03 Million |
| Other Expenses | 85 Thousand | -929 Thousand | -10.34 Million | -17.83 Million | -4.54 Million | -1.24 Million |
| Cost and Expenses | 66.44 Million | 69.52 Million | 71.88 Million | 314.58 Million | 63.01 Million | 80.56 Million |
| Operating Income | -66.44 Million | -69.5 Million | -71.86 Million | -314.49 Million | -62.97 Million | -80.51 Million |
| Interest Expense | - | - | 366 Thousand | - | - | - |
| Income Tax Expense | -1.00 | 3.51 Million | -65 Thousand | 13.24 Million | -6.2 Million | -3.77 Million |
| Earnings before Tax | -66.35 Million | -65 Million | -85.77 Million | -327.26 Million | -61.31 Million | -77.98 Million |
| Net Income | -66.35 Million | -65 Million | -85.77 Million | -327.26 Million | -61.31 Million | -77.98 Million |
| Earnings Per Share Basic | -0.35 | -0.38 | -0.51 | - | -0.37 | -0.53 |
| Earnings Per Share Diluted | -0.35 | -0.38 | -0.51 | - | -0.37 | -0.53 |
| Weighted Average Shares Outstanding | 190.02 Million | 169.12 Million | 168.33 Million | 156.93 Million | 167.64 Million | 146.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 190.02 Million | 169.12 Million | 168.33 Million | 156.93 Million | 167.64 Million | 146.79 Million |
| Gross Margin | - | -160.59 | -2601.90 | -2555.99 | -82.07 | -85.20 |
| EBIT Margin | - | -2997.68 | -3259.62 | - | -1381.47 | -1747.16 |
| Profit Margin | - | -2954.55 | -4084.67 | -3444.89 | -1425.93 | -1772.48 |
| EBITDA | -62.79 Million | -65.94 Million | -68.45 Million | - | -59.4 Million | -76.87 Million |
| Earnings Before Tax Margin | - | -3159.27 | -3422.10 | -3310.44 | -1464.53 | -1829.95 |
6383
6884
5481
ELAN
A31
4071